Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
21.57
+0.36 (1.70%)
At close: Apr 6, 2026, 4:00 PM EDT
21.69
+0.12 (0.56%)
After-hours: Apr 6, 2026, 4:10 PM EDT
Lyell Immunopharma Employees
Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.
Employees
300
Change (1Y)
76
Growth (1Y)
33.93%
Revenue / Employee
$120
Profits / Employee
-$914,827
Market Cap
502.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 300 | 76 | 33.93% | 300 | 0 |
| Dec 31, 2023 | 224 | -50 | -18.25% | 224 | 0 |
| Dec 31, 2022 | 274 | 55 | 25.11% | 274 | 0 |
| Dec 31, 2021 | 219 | 29 | 15.26% | 219 | 0 |
| Mar 31, 2021 | 190 | - | - | 188 | 2 |
| Dec 31, 2020 | 190 | - | - | 188 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| 4D Molecular Therapeutics | 196 |
| ADC Therapeutics | 193 |
| Rigel Pharmaceuticals | 174 |
| Entrada Therapeutics | 152 |
| Absci | 140 |
| Verastem | 102 |
| Upstream Bio | 75 |
| Larimar Therapeutics | 71 |
LYEL News
- 25 days ago - Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - GlobeNewsWire
- 4 weeks ago - Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer - GlobeNewsWire
- 6 weeks ago - Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewsWire
- 7 weeks ago - Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 5 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 - GlobeNewsWire
- 5 months ago - Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer - GlobeNewsWire
- 5 months ago - Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire